Jackson Creek Investment Advisors LLC Sells 2,739 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Jackson Creek Investment Advisors LLC decreased its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 3.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 88,331 shares of the biotechnology company’s stock after selling 2,739 shares during the period. Jackson Creek Investment Advisors LLC’s holdings in ADMA Biologics were worth $1,515,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp lifted its position in ADMA Biologics by 61.4% during the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock valued at $259,970,000 after purchasing an additional 4,945,063 shares during the period. Geode Capital Management LLC lifted its holdings in ADMA Biologics by 2.6% in the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock valued at $107,606,000 after buying an additional 137,989 shares during the period. Perpetual Ltd bought a new position in ADMA Biologics in the fourth quarter valued at approximately $62,300,000. Lord Abbett & CO. LLC acquired a new stake in ADMA Biologics during the 3rd quarter worth $61,858,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in ADMA Biologics by 1,144.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock worth $51,016,000 after acquiring an additional 2,613,482 shares during the period. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently issued reports on ADMA. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday. Raymond James raised their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th. Finally, HC Wainwright upped their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th.

ADMA Biologics Price Performance

ADMA opened at $16.91 on Friday. The stock has a market cap of $4.00 billion, a P/E ratio of 60.39 and a beta of 0.75. ADMA Biologics, Inc. has a 12 month low of $5.88 and a 12 month high of $23.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The company has a fifty day simple moving average of $16.67 and a 200 day simple moving average of $17.96.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.